ImmuCell (NASDAQ:ICCC) Stock Passes Below 200-Day Moving Average – What’s Next?

Posted by Defense World Staff on Dec 16th, 2025

ImmuCell Corporation (NASDAQ:ICCC – Get Free Report)’s share price crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $6.18 and traded as low as $6.02. ImmuCell shares last traded at $6.14, with a volume of 3,341 shares traded.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d)” rating on shares of ImmuCell in a research note on Monday, December 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, ImmuCell presently has an average rating of “Sell”.

Read Our Latest Stock Analysis on ImmuCell

ImmuCell Stock Performance

The company has a 50-day simple moving average of $5.79 and a two-hundred day simple moving average of $6.18. The company has a quick ratio of 1.76, a current ratio of 4.21 and a debt-to-equity ratio of 0.27. The firm has a market cap of $55.57 million, a PE ratio of 23.62 and a beta of 0.20.

ImmuCell (NASDAQ:ICCC – Get Free Report) last announced its earnings results on Thursday, November 13th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter. The business had revenue of $5.51 million for the quarter. ImmuCell had a net margin of 8.37% and a return on equity of 8.00%.

Hedge Funds Weigh In On ImmuCell

A hedge fund recently bought a new stake in ImmuCell stock. Steadtrust LLC bought a new stake in ImmuCell Corporation (NASDAQ:ICCC – Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 31,700 shares of the biotechnology company’s stock, valued at approximately $198,000. Steadtrust LLC owned 0.35% of ImmuCell at the end of the most recent reporting period. Institutional investors own 13.47% of the company’s stock.

ImmuCell Company Profile

(Get Free Report)

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.